Division of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM.
Department of Medicine, John H Stronger Hospital, Cook County, Chicago, IL.
Curr Probl Cardiol. 2023 Feb;48(2):101481. doi: 10.1016/j.cpcardiol.2022.101481. Epub 2022 Nov 8.
Coronavirus-19 (COVID-19), while primarily a respiratory virus, affects multiple organ systems, including the cardiovascular system. The relationship between COVID-19 and Myocarditis has been well established, but there are limited large-scale studies evaluating outcome of COVID-19 related Myocarditis. Using National Inpatient Sample (NIS) database, we compared patients with Myocarditis with and without COVID-19 infection. The primary outcome was in-hospital mortality. Secondary outcomes were acute kidney injury requiring hemodialysis, vasopressor use, mechanical ventilation, cardiogenic shock, mechanical circulatory support, sudden cardiac arrest, and length of hospitalization. A total of 17,970 patients were included in study; Myocarditis without COVID (n = 11,515, 64%) and Myocarditis with COVID-19 (n = 6,455, 36%). Patients with COVID-19 and Myocarditis had higher in-hospital mortality compared to those with Myocarditis alone (30.7% vs 6.4%, odds ratio 4.8, 95% CI 3.7-6.3, P< 0.001). That cohort also had significantly higher rates of vasopressor use, mechanical ventilation, sudden cardiac arrest, and acute kidney injury requiring hemodialysis. Given the poor outcome seen in COVID-19 related Myocarditis cohort, further work is needed for development of directed therapies for COVID-19-related Myocarditis.
新型冠状病毒肺炎(COVID-19)虽然主要是一种呼吸道病毒,但会影响多个器官系统,包括心血管系统。COVID-19 与心肌炎之间的关系已得到充分证实,但评估 COVID-19 相关心肌炎结局的大规模研究有限。本研究利用国家住院患者样本(NIS)数据库,比较了 COVID-19 感染与非 COVID-19 感染相关心肌炎患者的结局。主要结局是住院期间死亡率。次要结局包括需要血液透析的急性肾损伤、血管加压素使用、机械通气、心源性休克、机械循环支持、心脏骤停和住院时间。共纳入 17970 例患者;非 COVID 相关心肌炎(n=11515,64%)和 COVID-19 相关心肌炎(n=6455,36%)。与单纯心肌炎患者相比,COVID-19 合并心肌炎患者的住院期间死亡率更高(30.7%比 6.4%,优势比 4.8,95%CI 3.7-6.3,P<0.001)。该队列的血管加压素使用、机械通气、心脏骤停和需要血液透析的急性肾损伤发生率也明显更高。鉴于 COVID-19 相关心肌炎患者的不良结局,需要进一步开展针对 COVID-19 相关心肌炎的靶向治疗研究。